Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection

Marco Bruno Morelli; Chiara Bongiovanni; Silvia Da Pra; Carmen Miano; Francesca Sacchi; Mattia Lauriola; Gabriele D’Uva

doi:10.3389/fcvm.2022.847012

journal article Open Access Apr 15, 2022

Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection

Marco Bruno Morelli Chiara Bongiovanni Silvia Da Pra Carmen Miano Francesca Sacchi Mattia Lauriola

Gabriele D’Uva

Frontiers in Cardiovascular Medicine Vol. 9 · Frontiers Media SA

View at Publisher Save 10.3389/fcvm.2022.847012

Abstract

Chemotherapy and targeted therapies have significantly improved the prognosis of oncology patients. However, these antineoplastic treatments may also induce adverse cardiovascular effects, which may lead to acute or delayed onset of cardiac dysfunction. These common cardiovascular complications, commonly referred to as cardiotoxicity, not only may require the modification, suspension, or withdrawal of life-saving antineoplastic therapies, with the risk of reducing their efficacy, but can also strongly impact the quality of life and overall survival, regardless of the oncological prognosis. The onset of cardiotoxicity may depend on the class, dose, route, and duration of administration of anticancer drugs, as well as on individual risk factors. Importantly, the cardiotoxic side effects may be reversible, if cardiac function is restored upon discontinuation of the therapy, or irreversible, characterized by injury and loss of cardiac muscle cells. Subclinical myocardial dysfunction induced by anticancer therapies may also subsequently evolve in symptomatic congestive heart failure. Hence, there is an urgent need for cardioprotective therapies to reduce the clinical and subclinical cardiotoxicity onset and progression and to limit the acute or chronic manifestation of cardiac damages. In this review, we summarize the knowledge regarding the cellular and molecular mechanisms contributing to the onset of cardiotoxicity associated with common classes of chemotherapy and targeted therapy drugs. Furthermore, we describe and discuss current and potential strategies to cope with the cardiotoxic side effects as well as cardioprotective preventive approaches that may be useful to flank anticancer therapies.

Topics

No keywords indexed for this article. Browse by subject →

References

297

[1]

Lambert "Controversies in the definition of cardiotoxicity: do we care? – American college of cardiology." Am Coll Cardiol. (2016)

[2]

Cardinale "Cardiotoxicity of anthracyclines." Front Cardiovasc Med. (2020) 10.3389/fcvm.2020.00026

[3]

Menna "Primary prevention strategies for anthracycline cardiotoxicity: a brief overview." Chemotherapy. (2017) 10.1159/000455823

[4]

Mercurio "Models of heart failure based on the cardiotoxicity of anticancer drugs." J Card Fail. (2016) 10.1016/j.cardfail.2016.04.008

[5]

Menna "Anthracycline cardiotoxicity." Expert Opin Drug Saf. (2012) 10.1517/14740338.2011.589834

[6]

Minotti "Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity." Pharmacol Rev. (2004) 10.1124/pr.56.2.6

[7]

Sawyer "Anthracyclines and heart failure." N Engl J Med. (2013) 10.1056/nejmcibr1214975

[8]

Seidman "Cardiac dysfunction in the trastuzumab clinical trials experience." J Clin Oncol. (2002) 10.1200/jco.2002.20.5.1215

[9]

Plana "Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American society of echocardiography and the European association of cardiovascular imaging." Eur Hear J Cardiovasc Imaging. (2014) 10.1093/ehjci/jeu192

[10]

Vaduganathan "Cardiovascular risk assessment in oncological clinical trials: is there a role for centralized events adjudication?" Eur J Heart Fail. (2016) 10.1002/ejhf.457

[11]

Ewer "Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity." J Clin Oncol. (2005) 10.1200/jco.2005.05.827

[12]

Suter "Cancer drugs and the heart: importance and management." Eur Heart J. (2013) 10.1093/eurheartj/ehs181

[13]

Ky "Emerging paradigms in cardiomyopathies associated with cancer therapies." Circ Res. (2013) 10.1161/circresaha.113.300218

[14]

Gammella "The role of iron in anthracycline cardiotoxicity." Front Pharmacol. (2014) 10.3389/fphar.2014.00025

[15]

Hahn "Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies." J Am Heart Assoc. (2014) 10.1161/jaha.113.000665

[16]

Molinaro "Recent advances on pathophysiology, diagnostic and therapeutic insights in cardiac dysfunction induced by antineoplastic drugs." Biomed Res Int. (2015) 10.1155/2015/138148

[17]

Albini "Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention." J Natl Cancer Inst. (2010) 10.1093/jnci/djp440

[18]

Swain "Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials." Cancer. (2003) 10.1002/cncr.11407

[19]

Von Hoff "Risk factors for doxorubicin-induced congestive heart failure." Ann Intern Med. (1979) 10.7326/0003-4819-91-5-710

[20]

Shaikh "Mitoxantrone-induced cardiotoxicity in acute myeloid leukemia-a velocity vector imaging analysis." Echocardiography. (2016) 10.1111/echo.13245

[21]

Damiani "Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone." Arch Toxicol. (2016) 10.1007/s00204-016-1759-y

[22]

Saletan "Mitoxantrone: an active, new antitumor agent with an improved therapeutic index." Cancer Treat Rev. (1987) 10.1016/0305-7372(87)90021-1

[23]

Qiu "Risk factors for anthracycline-induced cardiotoxicity." Front Cardiovasc Med. (2021) 10.3389/fcvm.2021.736854

[24]

Tromp "Cardio-oncology: progress in diagnosis and treatment of cardiac dysfunction." Clin Pharmacol Ther. (2017) 10.1002/cpt.614

[25]

Chang "Pharmacogenetics of chemotherapy-induced cardiotoxicity." Curr Oncol Rep. (2018) 10.1007/s11912-018-0696-8

[26]

Duan "Mapping genes that contribute to daunorubicin-induced cytotoxicity." Cancer Res. (2007) 10.1158/0008-5472.can-06-4431

[27]

Blanco "Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes–a report from the children’s oncology group." J Clin Oncol. (2012) 10.1200/jco.2011.34.8987

[28]

Semsei "ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia." Cell Biol Int. (2012) 10.1042/cbi20110264

[29]

Krajinovic "Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia." Pharmacogenomics J. (2016) 10.1038/tpj.2015.63

[30]

Visscher "Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children." Pharmacogenomics. (2015) 10.2217/pgs.15.61

[31]

Miranda "Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin." Blood. (2003) 10.1182/blood-2003-03-0869

[32]

Yang "Potential gene association studies of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis." Front Cardiovasc Med. (2021) 10.3389/fcvm.2021.651269

[33]

Cardinale "Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy." Circulation. (2015) 10.1161/circulationaha.114.013777

[34]

Renu "Molecular mechanism of doxorubicin-induced cardiomyopathy – an update." Eur J Pharmacol. (2018) 10.1016/j.ejphar.2017.10.043

[35]

Wallace "Mitochondrial determinants of doxorubicin-induced cardiomyopathy." Circ Res. (2020) 10.1161/circresaha.119.314681

[36]

Murabito "Mechanisms of anthracycline-induced cardiotoxicity: is mitochondrial dysfunction the answer?" Front Cardiovasc Med. (2020) 10.3389/fcvm.2020.00035

[37]

Tocchetti "From molecular mechanisms to clinical management of antineoplastic drug-induced cardiovascular toxicity: a translational overview." Antioxid Redox Signal. (2019) 10.1089/ars.2016.6930

[38]

Ghigo "New signal transduction paradigms in anthracycline-induced cardiotoxicity." Biochim Biophys Acta. (2016) 10.1016/j.bbamcr.2016.01.021

[39]

Pagliaro "Redox signalling and cardioprotection: translatability and mechanism." Br J Pharmacol. (2015) 10.1111/bph.12975

[40]

Bonora "Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles." Nat Rev Cardiol. (2019) 10.1038/s41569-018-0074-0

[41]

Brown "Expert consensus document: mitochondrial function as a therapeutic target in heart failure." Nat Rev Cardiol. (2017) 10.1038/nrcardio.2016.203

[42]

Murphy "Mitochondrial function, biology, and role in disease: a scientific statement from the american heart association." Circ Res. (2016) 10.1161/res.0000000000000104

[43]

Aon "Mitochondrial network energetics in the heart." Wiley Interdiscip Rev Syst Biol Med. (2012) 10.1002/wsbm.1188

[44]

Ichikawa "Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation." J Clin Invest. (2014) 10.1172/jci72931

[45]

Zhang "Identification of the molecular basis of doxorubicin-induced cardiotoxicity." Nat Med. (2012) 10.1038/nm.2919

[46]

Davies "Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase." J Biol Chem. (1986) 10.1016/s0021-9258(17)35746-0

[47]

Tullio "Redox balance and cardioprotection." Basic Res Cardiol. (2013) 10.1007/s00395-013-0392-7

[48]

Penna "Cardioprotection: a radical view free radicals in pre and postconditioning." Biochim Biophys Acta. (2009) 10.1016/j.bbabio.2009.02.008

[49]

Regulated cell death pathways in doxorubicin-induced cardiotoxicity

Effimia Christidi, Liam R. Brunham

Cell Death & Disease 2021 10.1038/s41419-021-03614-x

[50]

Qin "The role of iron in doxorubicin-induced cardiotoxicity: recent advances and implication for drug delivery." J Mater Chem B. (2021) 10.1039/d1tb00551k

Showing 50 of 297 references

Cited By

149

Mitochondrial Dysfunction in Cardiac Diseases: Insights into Pathophysiology and Clinical Outcomes

Syed Shadab Ahmad, Javed Akhtar Ansari · 2026

Current Cardiology Reviews

Impact of Pre-Existing Cardiovascular and Metabolic Conditions on the Development of Heart Failure After Paclitaxel Therapy　― Real-World Study Based on a Nationwide Claims Database in Japan ―

Shiori Iwane, Masayuki Tanaka · 2026

Circulation Reports

A PI3K Inhibitor with Low Cardiotoxicity and Its Synergistic Inhibitory Effect with Gilteritinib in Acute Myelogenous Leukemia (AML) Cells

Tianze Wu, Yi Chen · 2025

Molecules

Atrial Strain Assessment for the Early Detection of Cancer Therapy-Related Cardiac Dysfunction in Breast Cancer Women (The STRANO STUDY: Atrial Strain in Cardio-Oncology)

Daniela Di Lisi, Antonella Moreo · 2023

Journal of Clinical Medicine

Metrics

149

Citations

297

References

Details

Published: Apr 15, 2022
Vol/Issue: 9
License: View

Authors

Funding

Ministero della Salute Award: Ricerca Corrente - IRCCS MultiMedica

Fondazione Cariplo Award: GR 2017-0800

Cite This Article

Marco Bruno Morelli, Chiara Bongiovanni, Silvia Da Pra, et al. (2022). Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection. Frontiers in Cardiovascular Medicine, 9. https://doi.org/10.3389/fcvm.2022.847012

Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection

You May Also Like